Concepedia

SARS-CoV-2-specific T cell therapy for severe COVID-19: a randomized phase 1/2 trial

George Karavalakis, Efthymia Papadopoulou, Aliki Xochelli, Zoi Bousiou, Anastasios Vogiatzoglou, Penelope‐Georgia Papayanni, Aphrodite Georgakopoulou, Maria Giannaki, Fani Stavridou, Ioanna Vallianou,

Nature Medicine · 2023 · 35 citations · 47 references

Concepts

Life SciencesImmunologyInfectious DiseasesCell TherapyClinical ImmunologyImmunotherapyAntiviral TherapyCell-based ImmunotherapyCell-mediated ImmunityRegulatory T CellsT Cell Activation ControlT Cell BiologyAdoptive T Cell Therapy CombinationsSars-cov-2 Antiviral TherapySars-cov-2 InfectionT Cell Response InductionT Cell-based ImmunotherapyT-cell Therapy

References

47

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Xiaobo Yang, Yu Yuan, Jiqian Xu et al. · The Lancet Respiratory Medicine · 2020 · 10.7K citations · Full text

Medicine, Infectious Diseases, Internal Medicine +14

Dexamethasone in Hospitalized Patients with Covid-19

New England Journal of Medicine · 2020 · 10.1K citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +15

CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials

BMJ · 2010 · 8.7K citations · Full text

Public Health, Health Policy, Clinical Epidemiology +16

Dexamethasone in Hospitalized Patients with Covid-19.

Peter Horby, Wei Shen Lim, Jonathan Emberson et al. · DiRROS repository (University of Maribor) · 2020 · 8K citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +15

Remdesivir for the Treatment of Covid-19 — Final Report

John H. Beigel, Kay M Tomashek, Lori E. Dodd et al. · New England Journal of Medicine · 2020 · 7.7K citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +15